With GLP-1 receptor agonists now crowding the market in both injectable and oral forms, clinicians and patients face a real dilemma: which formulation actually delivers the broadest cardiometabolic benefit, not just weight loss? A new systematic review and network meta-analysis published in Diabetes, Obesity & Metabolism attempts to answer that with a composite ranking tool applied across 19 randomized controlled trials enrolling more than 13,000 adults.

The analysis constructed a Cardiometabolic Efficacy Index (CEI) — a ranked composite score from 0 to 1 — integrating seven endpoints: total body weight reduction, triglycerides, HDL cholesterol, LDL cholesterol, waist circumference, HbA1c, and systolic blood pressure. Subcutaneous semaglutide 7.2 mg led the field with a CEI of 0.86, while orforglipron 36 mg (the bioequivalent of the newly approved Foundayo 17.2 mg oral tablet) and subcutaneous semaglutide 2.4 mg followed at 0.68 and 0.66, respectively. All three top performers achieved placebo-adjusted weight reductions exceeding 10%. Notably, among oral-only agents in adults without type 2 diabetes, orforglipron 36 mg matched oral semaglutide 25 mg in CEI (0.67 vs 0.63), suggesting the newer small-molecule oral option may be competitive without requiring refrigeration or the strict fasting protocol tied to oral semaglutide.

The composite CEI approach is methodologically ambitious but carries real limitations. Network meta-analysis depends on the transitivity assumption — that trial populations and comparators are sufficiently similar — which is difficult to guarantee across studies spanning nearly a decade with evolving baseline characteristics. The equal weighting of all seven endpoints in the CEI may not reflect clinical priorities, since a cardiologist and an endocrinologist might weight HbA1c and LDL very differently. Additionally, head-to-head trial data between orforglipron and semaglutide at matched doses remain sparse. Still, as an evidence-synthesis framework for comparing a rapidly expanding drug class, this analysis provides a useful scaffold. For adults prioritizing broad cardiovascular risk reduction alongside weight management, higher-dose agents appear to offer meaningfully superior profiles — though individual tolerability, cost, and administration preferences will continue to drive real-world decisions.